Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

التفاصيل البيبلوغرافية
العنوان:	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
المؤلفون:	Gay, Francesca ^{, }, Musto, Pellegrino ^*, Rota-Scalabrini, Delia, Bertamini, Luca, Belotti, Angelo, Galli, Monica, Offidani, Massimo, Zamagni, Elena, Ledda, Antonio, Grasso, Mariella, Ballanti, Stelvio, Spadano, Antonio, Cea, Michele, Patriarca, Francesca, D'Agostino, Mattia, Capra, Andrea, Giuliani, Nicola, de Fabritiis, Paolo, Aquino, Sara, Palmas, Angelo, Gamberi, Barbara, Zambello, Renato, Petrucci, Maria Teresa, Corradini, Paolo, Cavo, Michele, Boccadoro, Mario
المصدر:	In The Lancet Oncology December 2021 22(12):1705-1720
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	14702045
DOI:	10.1016/S1470-2045(21)00535-0